Details for Patent: 4,913,906

Summary for Patent: 4,913,906

Patent landscape, scope, and claims:

Title:	Novel controlled release dosage form of valproic acid
Abstract:	The invention relates to controlled release pharmaceutical compositions. These contain as active ingredient valproic acid, a salt of valproic acid, an ester of valproic acid, Valpromide, or any other pharmaceutically acceptable derivative of valproic acid which upon administration to humans provides a serum level of valproic acid, in combination with an additive which is selected from physiologically acceptable polymeric substances and from native proteins. The active ingredient is usually in the range of from 10 to 80 weight percent. The novel pharmaceutical compositions are prepared by applying a high pressure to a mixture of the ingredients. They result in a prolonged serum level of the active ingredient.
Inventor(s):	Friedman; Michael (Jerusalem, IL), Bialer; Meir (Jerusalem, IL), Rubinstein; Avraham (Jerusalem, IL), Dufrovsky; Upd (Tel-Aviv, IL)
Assignee:
Application Number:	06/832,244
Patent Claim Types: see list of patent claims	Compound; Dosage form; Process;

Drugs Protected by US Patent 4,913,906

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 4,913,906

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Israel	74468	Feb 28, 1985

International Family Members for US Patent 4,913,906

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2009890
European Patent Office	0442012
Israel	74468